Gemcitabine + cisplatin (nasopharyngeal)
Checked 2026-09-09
Locoregionally advanced nasopharyngeal carcinoma, induction before chemoradiation; recurrent or metastatic disease with toripalimab
One cycle
every 21 days × 3 · about 9 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Gemcitabine Nucleoside analogue (deoxycytidine) | 1,000 mg/m² | IV | D1, 8 | |
Cisplatin Cytotoxic chemotherapy (platinum) | 80 mg/m² | IV | D1 | |
Toripalimab (recurrent or metastatic, JUPITER-02) Monoclonal antibody (anti-PD-1) | 240 mg | IV | D1 |
Cycles
3 induction (6 with toripalimab in metastatic disease)
21-day cycle
Emetogenicity
High (>90%)
G-CSF
Not routine
Used in
Trials
Products
Source
Zhang, NEJM 2019 (induction GP)
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.